%A LI Chen-Chen, FENG Ji-Feng %T Reversal for acquired resistance to EGFR inhibitors in lung cancer %0 Journal Article %D 2013 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2013.11.013 %P 843-846 %V 40 %N 11 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9253.shtml} %8 2013-11-08 %X Epidermal growth factor receptor (EGFR) inhibitors targeted therapy is the forward position means for nonsmall cell lung cancer. However, acquired resistance to EGFR inhibitors limits the development of targeted drugs. Using existing data on drug resistance in EGFRmutant lung cancer, this review discusses three basic approaches for overcoming resistance to EGFRtargeted therapies: intensification of EGFR inhibition, combination of EGFR inhibitors with other targeted therapies, and altering clinical management via alternate pathways.